600216 浙江医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入6,695,298-5.87%9,375,2177,794,1468,115,8059,129,094
减:营业总成本5,638,082-7.62%7,934,0247,681,6667,482,0257,932,301
    其中:营业成本4,184,975-1.85%5,406,5415,269,8795,318,2745,399,736
               财务费用(93,264)3,150.21%(4,958)(17,488)(37,966)93,110
               资产减值损失(94,216)-7.17%(263,899)(137,208)(117,141)(165,169)
公允价值变动收益21,365-697.08%(21,534)(10,099)(23,881)51,726
投资收益5,365-133.08%(8,069)(3,505)(32,626)41,815
    其中:对联营企业和合营企业的投资收益(6,736)-45.51%(9,643)(9,782)(3,806)(4,240)
营业利润1,048,29411.87%1,223,110380,158504,6161,179,437
利润总额1,046,30712.41%1,212,282363,279491,3881,153,532
减:所得税费用179,5754.25%192,03186,485128,775268,972
净利润866,73214.26%1,020,252276,794362,614884,559
减:非控股权益(66,416)-27.09%(140,259)(152,845)(176,956)(160,763)
股东净利润933,1489.83%1,160,511429,640539,5701,045,322

市场价值指针
每股收益 (元) *0.97010.23%1.2100.4500.5601.090
每股派息 (元) *----0.3700.1500.1700.330
每股净资产 (元) *11.4966.90%11.0739.9809.5949.096
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容